Literature DB >> 7987673

Hageman factor and its binding sites are present in senile plaques of Alzheimer's disease.

O Yasuhara1, D G Walker, P L McGeer.   

Abstract

Hageman factor (HF) or factor XII participates in several defense systems of the body. These include coagulation, fibrinolysis and complement activation. We investigated the expression of HF and its mRNA in control and Alzheimer's disease (AD) brain, using immunohistochemistry and polymerase-chain reaction (PCR) techniques. HF mRNA was detected in control and AD brain extracts, indicating that HF can be produced by endogenous brain cells. HF-like immunoreactivity was present in residual serum of capillaries in both control and AD brain, consistent with its known presence in the circulation. In addition, AD senile plaques were stained. The staining was dramatically enhanced when AD sections were incubated with solutions containing HF, indicating that plaques contain not only HF but also binding sites for HF. The enhanced staining was eliminated by pretreatment of solutions with the HF-binding agent kaolin. It was also eliminated by pretreatment of sections with protamine, an agent which strongly binds to negative surfaces. These data suggest that negatively charged surfaces in plaques might bind HF in vivo. Since HF can be activated by contact with negative surfaces, locally released HF could be playing a role in initiating a variety of inflammatory responses in AD brain.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7987673     DOI: 10.1016/0006-8993(94)90484-7

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  16 in total

1.  Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner.

Authors:  L Bergamaschini; S Canziani; B Bottasso; M Cugno; P Braidotti; A Agostoni
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

Review 2.  Interactions of β-amyloid peptide with fibrinogen and coagulation factor XII may contribute to Alzheimer's disease.

Authors:  Hyung J Ahn; Zu-Lin Chen; Daria Zamolodchikov; Erin H Norris; Sidney Strickland
Journal:  Curr Opin Hematol       Date:  2017-09       Impact factor: 3.284

Review 3.  Inflammation and Alzheimer's disease.

Authors:  H Akiyama; S Barger; S Barnum; B Bradt; J Bauer; G M Cole; N R Cooper; P Eikelenboom; M Emmerling; B L Fiebich; C E Finch; S Frautschy; W S Griffin; H Hampel; M Hull; G Landreth; L Lue; R Mrak; I R Mackenzie; P L McGeer; M K O'Banion; J Pachter; G Pasinetti; C Plata-Salaman; J Rogers; R Rydel; Y Shen; W Streit; R Strohmeyer; I Tooyoma; F L Van Muiswinkel; R Veerhuis; D Walker; S Webster; B Wegrzyniak; G Wenk; T Wyss-Coray
Journal:  Neurobiol Aging       Date:  2000 May-Jun       Impact factor: 4.673

4.  Depletion of coagulation factor XII ameliorates brain pathology and cognitive impairment in Alzheimer disease mice.

Authors:  Zu-Lin Chen; Alexey S Revenko; Pradeep Singh; A Robert MacLeod; Erin H Norris; Sidney Strickland
Journal:  Blood       Date:  2017-02-27       Impact factor: 22.113

5.  Up-regulated production and activation of the complement system in Alzheimer's disease brain.

Authors:  K Yasojima; C Schwab; E G McGeer; P L McGeer
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

6.  The structure of the FnI-EGF-like tandem domain of coagulation factor XII solved using SIRAS.

Authors:  D X Beringer; L M J Kroon-Batenburg
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2013-01-26

7.  The Alzheimer's disease peptide β-amyloid promotes thrombin generation through activation of coagulation factor XII.

Authors:  D Zamolodchikov; T Renné; S Strickland
Journal:  J Thromb Haemost       Date:  2016-02-29       Impact factor: 5.824

Review 8.  Blood will out: vascular contributions to Alzheimer's disease.

Authors:  Sidney Strickland
Journal:  J Clin Invest       Date:  2018-02-01       Impact factor: 14.808

9.  Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation.

Authors:  Coen Maas; José W P Govers-Riemslag; Barend Bouma; Bettina Schiks; Bouke P C Hazenberg; Henk M Lokhorst; Per Hammarström; Hugo ten Cate; Philip G de Groot; Bonno N Bouma; Martijn F B G Gebbink
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

Review 10.  Heparin oligosaccharides as potential therapeutic agents in senile dementia.

Authors:  Qing Ma; Umberto Cornelli; Israel Hanin; Walter P Jeske; Robert J Linhardt; Jeanine M Walenga; Jawed Fareed; John M Lee
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.